drugset / Trial / NCT02989844
Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, multi-center Phase II trial using IL-15 super-agonist complex (N-803 formerly known as Alt-803) maintenance after allogeneic hematopoietic cell transplant (alloHCT) for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS).
Timeline
- Start
- 2017-04-12
- Primary completion
- 2022-03-19
- Completion
- 2022-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | N-803 | Protein / enzyme biologic | 6 ug/kg | Subcutaneous |